News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors:
Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: James Heins
Tel: +1 203 682 8251
James.Heins@icrinc.com

Sirnaomics at Opt Congress
March 11, 2019 Sirnaomics to Present at the 4th Annual OPT: Discovery, Development & Delivery

Sirnaomics announced that the Company’s management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts.

Sirnaomics AsiaTIDES
February 25, 2019 Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Live

Sirnaomics announced that the Company will present preclinical data from the use of its RNAi technology program in a liver cancer mouse model at AsiaTIDES: Ogligonucleotide & Peptide Therapeutics taking place in Tokyo, Japan on February 28 – March 1, 2019.

Sirnaomics News Placeholder 03
January 30, 2019 Sirnaomics to Present at 2019 BIO CEO & Investor Conference

Sirnaomics announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 11-12.

Sirnaomics at JP Morgan Healthcare Annual Conference
January 6, 2019 CEO Dr. Patrick Lu presents at the CTIC Healthcare Summit

Sirnaomics’ president and CEO Dr. Patrick Lu presents at the CTIC Healthcare Summit on Jan. 6th, 2019, before the 37th JP Morgan Healthcare Conference in San Francisco.

Sirnaomics News Placeholder 02
December 19, 2018 Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of NMSC

Sirnaomics announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s proposed trial design for a Phase 2 clinical study to evaluate its lead product candidate, STP705, for the treatment of in situ Squamous Cell Carcinoma Nonmelanoma Skin Cancer (NMSC).

1 2 3 4 7